Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01047007 | A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005 | terminated | Phase 1 | 11 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 |
| clinicaltrials |
| NCT04551885 | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 12 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04865159 | Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 6 | Kura Oncology, Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05069935 | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 16 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05698888 | Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors | terminated | Phase 1 | 2 | Virtuoso BINco, Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | terminated | Phase 1 | 8 | Biotheryx, Inc.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05470933 | A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors | terminated | Phase 1 | 7 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 1, 2023 | clinicaltrials |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | terminated | Phase 1 | 2 | AeRang KimOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03139370 | Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04467853 | A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors | terminated | Phase 1 | 34 | Shanghai East HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT04729725 | SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03926143 | A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies | terminated | Phase 2 | 9 | BayerINDUSTRY | 4 | Aug 4, 2023 | clinicaltrials |
| NCT05129280 | A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors | terminated | Phase 1 | 23 | Hoffmann-La RocheINDUSTRY | 6 | Aug 4, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04214093 | A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | terminated | Phase 1 | 9 | AstraZenecaINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04601285 | A Phase I Study of JS108 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 25 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT04081298 | eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors(MiVSEEV) | terminated | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03333031 | A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies | terminated | Phase 1 | 7 | Herbert LyerlyOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | Dracen Pharmaceuticals, Inc.INDUSTRY | 5 | Jun 12, 2023 | clinicaltrials |
| NCT03871855 | A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors | terminated | Phase 1 | 8 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04186637 | An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies(NEON-1) | terminated | Phase 1 | 62 | Alpine Immune Sciences, Inc.INDUSTRY | 2 | Jun 5, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04849273 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | terminated | Phase 1 | 11 | Turning Point Therapeutics, Inc.INDUSTRY | 3 | May 26, 2023 | clinicaltrials |
| NCT03892018 | The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol | terminated | Phase 1 | 29 | Athenex, Inc.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT03588039 | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 34 | Athenex, Inc.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT02761694 | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | terminated | Phase 1 | 78 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT03884517 | Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer | terminated | Phase 1 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00886782 | A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 28, 2023 | clinicaltrials |
| NCT04775680 | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 25 | Adagene (Suzhou) LimitedINDUSTRY | 1 | Apr 24, 2023 | clinicaltrials |
| NCT04696848 | The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Tae Won KimOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04381325 | A Study of MSB0254 Injection in Advanced Solid Tumors | terminated | Phase 1 | 25 | Suzhou Transcenta Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04746612 | First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors | terminated | Phase 1 | 22 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Mar 30, 2023 | clinicaltrials |
| NCT05010525 | A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors(REACH) | terminated | Phase 1 / Phase 2 | 8 | Shanghai Antengene Corporation LimitedINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05008445 | Study of LM-102 in Patients With Advance Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | LaNova Medicines Development Co., Ltd.INDUSTRY | 1 | Mar 9, 2023 | clinicaltrials |
| NCT04557384 | A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer | terminated | Phase 1 | 3 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 27, 2023 | clinicaltrials |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 41 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT04835714 | A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04518137 | A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH) | terminated | Phase 2 | 5 | Shanghai Antengene Corporation LimitedINDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT04800627 | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor | terminated | Phase 1 / Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT04372706 | RTX-240 Monotherapy and in Combination With Pembrolizumab | terminated | Phase 1 / Phase 2 | 69 | Rubius TherapeuticsINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT03815682 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | terminated | Phase 1 | 23 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03195764 | Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors | terminated | Phase 1 | 21 | Taivex Therapeutics CorporationINDUSTRY | 1 | Nov 18, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 21, 2023source: clinicaltrials